Literature DB >> 24029937

Novel methods for the investigation of human hypertrophic scarring and other dermal fibrosis.

Dariush Honardoust1, Peter Kwan, Moein Momtazi, Jie Ding, Edward E Tredget.   

Abstract

Hypertrophic scar (HTS) represents the dermal equivalent of fibroproliferative disorders that occur after injury involving the deep dermis while superficial wounds to the skin heal with minimal or no scarring. HTS is characterized by progressive deposition of collagen that occurs with high frequency in adult dermal wounds following traumatic or thermal injury. Increased levels of transforming growth factor-β1 (TGF-β1), decreased expression of small leucine-rich proteoglycans (SLRPs), and/or fibroblast subtypes may influence the development of HTS. The development of HTS is strongly influenced by the cellular and molecular properties of fibroblast subtypes, where cytokines such as fibrotic TGF-β1 and CTGF as well as the expression of SLRPs, particularly decorin and fibromodulin, regulate collagen fibrillogenesis and the activity of TGF-β1. Reduced anti-fibrotic molecules in the ECM of the deep dermis and the distinctive behavior of the fibroblasts in this region of the dermis which display increased sensitivity to TGF-β1's biological activity contribute to the development of HTS following injury to the deep dermis. By comparing the cellular and molecular differences involved in deep and superficial wound healing in an experimental wound scratch model in humans that has both superficial and deep injuries within the same excisional model, our aim is to increase our understanding of how tissue repair following injury to the deep dermis can be changed to promote healing with a similar pattern to healing that occurs following superficial injury that results in no or minimal scarring. Studying the characteristics of superficial dermal injuries that heal with minimal scarring will help us identify therapeutic approaches for tissue engineering and wound healing. In addition, our ability to develop novel therapies for HTS is hampered by limitations in the available animal models used to study this disorder in vivo. We also describe a nude mouse model of transplanted human skin that develops a hypertrophic proliferative scar consistent morphologically and histologically with human HTS, which can be used to test novel treatment options for these dermal fibrotic conditions.

Entities:  

Mesh:

Year:  2013        PMID: 24029937     DOI: 10.1007/978-1-62703-505-7_11

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  10 in total

1.  Identification of sirtuin 1 as a promising therapeutic target for hypertrophic scars.

Authors:  Xiao-Zhi Bai; Jia-Qi Liu; Long-Long Yang; Lei Fan; Ting He; Lin-Lin Su; Ji-Hong Shi; Chao-Wu Tang; Zhao Zheng; Da-Hai Hu
Journal:  Br J Pharmacol       Date:  2016-03-23       Impact factor: 8.739

Review 2.  Hypertrophic Scarring: Current Knowledge of Predisposing Factors, Cellular and Molecular Mechanisms.

Authors:  Layla Nabai; Amir Pourghadiri; Aziz Ghahary
Journal:  J Burn Care Res       Date:  2020-01-30       Impact factor: 1.845

3.  MicroRNA-494 targets PTEN and suppresses PI3K/AKT pathway to alleviate hypertrophic scar formation.

Authors:  Ting He; Yue Zhang; Yang Liu; Hongtao Wang; Wanfu Zhang; Jiaqi Liu; Na Li; Yan Li; Luxu Wang; Songtao Xie; Dahai Hu
Journal:  J Mol Histol       Date:  2019-05-08       Impact factor: 2.611

4.  Effects of Apremilast on Induced Hypertrophic Scar of Rabbits.

Authors:  D Nidhal Ghazy; A Rahmah Abu-Raghif
Journal:  Arch Razi Inst       Date:  2021-12-30

5.  Compression therapy affects collagen type balance in hypertrophic scar.

Authors:  Shawn Tejiram; Jenny Zhang; Taryn E Travis; Bonnie C Carney; Abdulnaser Alkhalil; Lauren T Moffatt; Laura S Johnson; Jeffrey W Shupp
Journal:  J Surg Res       Date:  2015-11-05       Impact factor: 2.192

6.  A Translational Animal Model for Scar Compression Therapy Using an Automated Pressure Delivery System.

Authors:  A Alkhalil; S Tejiram; T E Travis; N J Prindeze; B C Carney; L T Moffatt; L S Johnson; J Ramella-Roman; J W Shupp
Journal:  Eplasty       Date:  2015-07-02

7.  Tetramethylpyrazine Induces Apoptosis and Inhibits Proliferation of Hypertrophic Scar-Derived Fibroblasts via Inhibiting the Phosphorylation of AKT.

Authors:  Xue Wu; Zheng Wang; Gaofeng Wu; Xiaofan Xu; Jian Zhang; Yan Li; Hong Zhang; Shuzhen Guo
Journal:  Front Pharmacol       Date:  2020-05-05       Impact factor: 5.810

8.  Circular RNA HECTD1 knockdown inhibits transforming growth factor-beta/ small mothers against decapentaplegic (TGF-β/Smad) signaling to reduce hypertrophic scar fibrosis.

Authors:  Xiaojing Ge; Yute Sun; Youzhi Tang; Jing Lin; Fang Zhou; Gang Yao; Xin Su
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

9.  Autophagy protein LC3 regulates the fibrosis of hypertrophic scar by controlling Bcl-xL in dermal fibroblasts.

Authors:  Jihong Shi; Shan Shi; Bin Wu; Jian Zhang; Yan Li; Xue Wu; Julei Zhang; Kejia Wang; Bin Zhao; Weixia Cai; Xiaozhi Bai; Dahai Hu; Hao Guan
Journal:  Oncotarget       Date:  2017-09-08

10.  Inhibition of growth of Asian keloid cells with human umbilical cord Wharton's jelly stem cell-conditioned medium.

Authors:  Subramanian Arjunan; Shu Uin Gan; Mahesh Choolani; Vaishnevi Raj; Jane Lim; Arijit Biswas; Ariff Bongso; Chui Yee Fong
Journal:  Stem Cell Res Ther       Date:  2020-02-21       Impact factor: 6.832

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.